Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of durvalumab in stage III non-small cell lung cancer patients with PD-L1 expression

Next Previous
Trial Profile

Efficacy of durvalumab in stage III non-small cell lung cancer patients with PD-L1 expression

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

Most Recent Events

  • 08 Jun 2021 Results evaluating the utility of novel imaging biomarkers (radiomics) to distinguish patients with stage III NSCLC who will benefit from treatment from those likely to progress despite therapy, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
  • 22 Jun 2020 New trial record
  • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top